Biotech Companies Continue to Make Progress on ESG

Start
A Look at the Disclosure Practices of Small and Mid-Size Companies – In our report we continue to look at the progress that smaller public biotech companies have made in their reporting on environmental, social and governance (ESG) matters, building on our prior research. This year we reviewed the disclosure practices of 74 biotech companies with market capitalizations ranging from $1 billion to $10 billion as of June 30, 2023….
By: Fenwick & West LLP
Previous Story

Federal Government Releases Proposed Guidance for Exercising “March-In” Rights Under the Bayh-Dole Act: Implications for Pharmaceutical and Medical Technology Companies

Next Story

Arrested Intimidation